- Imagin Medical Inc. is a surgical imaging company helping to advance the use of blue light cystoscopy (“BLC”) in battling bladder cancer and reducing costs associated with these procedures
- Bladder cancer is the sixth most prevalent cancer in the United States, and the third most common in men, yet the most expensive to treat While early-stage cancer intervention involves illuminating the bladder with white light – the light that can be seen by the human eye – to visualize and resect tumors, historical use of white light has resulted in incomplete tumor removal and a greater than 50% recurrence rate
- BLC, a revolutionary surgical method using a tumor-staining dye to reveal bladder cancer, has increased the effectiveness of cystoscopy, but financial and functional obstacles have limited its adoption.
- Imagin’s proprietary technology will address these primary barriers., The company’s product is in the manufacturing stage and working toward FDA approval
Increasing patient demand for and clinical data in support of blue light cystoscopy’s value in detecting to bladder cancer is shining new light on Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, and the potential value of their proprietary technology, the patented i/Blue Imaging System.
New data and analyses presented at the 21st Annual Meeting of the Society of Urologic Oncology in December discussed the budgetary impact of using blue light cystoscopy in surveillance cystoscopies. According to a report on the presentation by Photocure, which markets the tumor-staining drug, Cysview™, for use in blue light applications, the drug didn’t significantly affect the cost of cystoscopies and resulted in finding tumor recurrences that would otherwise have been missed.
“We initiated this study because the utility of blue light cystoscopy (“BLC”) for surveillance in patients receiving BCG (Bacillus Calmette-Guerin immunotherapy) treatments is really not well understood. Thus, no recommendations exist in current guidelines,” stated Dr. Max Kates, assistant professor of Urology and Oncology, and co-director at the Bladder Cancer Multidisplinary Clinic in the The James Buchanan Brady Urologic Institute of Johns Hopkins School of Medicine (https://ibn.fm/ywQGR).
“The use of BLC with Cysview continues to inspire the scientific community as much as ever for improving the care of patients diagnosed with bladder cancer. These new abstracts highlight the role of the procedure throughout patient care, especially focusing on the impact on patient management when used in surveillance,” Photocure President and CEO Dan Schneider added. “The Budget Impact Model supports the favorable cost-benefit of blue light procedures including in the office setting, while reaffirming its superiority in detection of non-muscle-invasive bladder cancer compared to white light alone.”
A Urology Times report (https://ibn.fm/YwotL) noted that the use of BLC with hexaminolevulinate hydrochloride (“HCl”) (under the trade name Cysview) in conjunction with white light during initial transurethral resection of bladder tumors (“TURB”) “lowered costs by $4,660 over 5 years compared with use of white light cystoscopy alone. The investigators also observed that patients receiving BLC had a lower overall cancer burden compared with those receiving white light alone.”
Despite the American Urological Association’s recommendation in favor of using BLC, the technology is used in less than 10 percent of such procedures because of the high cost of equipment and the challenges surgeons face in switching back and forth between white light and blue light images to locate and resect the tumors (https://ibn.fm/yslrQ). And that’s where Imagin Medical comes in.
Imagin’s proprietary i/Blue Imaging (TM) System is compatible with almost any scope already in use by hospitals and surgical centers and enhances their functionality by making it possible for surgeons to see white light and blue light video side-by-side in real time as the bladder tumor resection procedure takes place.
Bladder cancer historically has been the sixth-most common cancer in the United States, one of the most common in men and the most expensive to treat, in part because of a 50 percent recurrence rate that is only exacerbated by surgeons’ inability to always detect and remove all existing tumors using only white light in procedures (https://ibn.fm/BdRjk).
Despite the economic difficulties imposed by the ongoing COVID-19 pandemic, Imagin advanced its technology to development of a working product last year. In 2021, working with Lighthouse Imaging, an FDA certified manufacturer, Imagin has moved to the manufacturing stage to complete pre-production of the i/Blue Imaging System and finalize test parameters to meet exacting FDA requirements (https://ibn.fm/AEglk).
For more information, visit the company’s website at www.ImaginMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.